SAB Biotherapeutics Inc. (SABSW)
0.08
0.00 (0.00%)
At close: Jan 15, 2025, 12:15 PM
Company Description
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV).
SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
SAB Biotherapeutics Inc.
| Country | United States |
| IPO Date | Oct 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Samuel J. Reich |
Contact Details
Address: 2100 East 54th Street North Sioux Falls, South Dakota United States | |
| Website | http://www.sabbiotherapeutics.com |
Stock Details
| Ticker Symbol | SABSW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T111 |
| ISIN Number | US78397T1117 |
| Employer ID | 85-3899721 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | Chief Executive Officer & Executive Chairman |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President & Chief Operating Officer |
| Christine E. Hamilton M.B.A. | Co-Founder & Independent Director |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President & Chief Medical Officer |
| Dr. Carlos N. Carillo Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President & Director |
| Dr. Edward D. Hamilton D.V.M. | Co-Founder & Board Observer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 4 | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 4 | Filing |
| Sep 09, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 4 | Filing |
| Aug 12, 2024 | S-8 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |
| Jul 31, 2024 | 3 | Filing |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 17, 2024 | 4 | Filing |